Harmonic Transformations

12/28/2025

12/28/2025

12/23/2025

A remarkable new study shows that a single high-equivalent dose of psilocybin in mice can rapidly increase neuroplasticity by repairing and creating new neural connections in the brain. Researchers observed structural remodeling of dendritic spines in the medial frontal cortex, effectively rewiring neural networks. (As seen in this Cell.com article: https://www.cell.com/cell/fulltext/S0092-8674(25)01305-4) These changes were network-specific, strengthening pathways tied to perception and the brain’s default mode network, while quieting repetitive cortical loops. This work deepens our understanding of how psilocybin may support mental health by reshaping large-scale brain connectivity.

Watch the video by Chase Hughes to learn more: https://www.youtube.com/watch?v=lZ3_GUilpnk

12/19/2025

People who regularly ate higher-fat cheese and cream had a lower risk of developing dementia over 25 years, according to a new study.

The study did not find similar benefits for low-fat cheese, low-fat cream or butter. Milk consumption, whether high- or low-fat, also did not lower dementia risk.

Read more: https://abcnews.visitlink.me/TQaSyI

12/19/2025

A recent Brazilian clinical trial, published in the Journal of Alzheimer’s Disease and widely reported in December 2025, marks a groundbreaking development in exploring cannabis for Alzheimer’s treatment.

Researchers at the Federal University of Latin American Integration conducted a phase 2, randomized, double-blind, placebo-controlled study involving elderly patients aged 60-80 with mild Alzheimer’s disease.

Building on prior animal studies showing low-dose THC restoring cognition in aged mice and a 2022 case report where microdosing improved symptoms in one patient over 22 months, this trial tested daily oral microdoses of a balanced cannabis extract containing approximately 0.3 mg THC and 0.3 mg CBD—far below psychoactive levels.

Over 24-26 weeks, the treatment group showed stabilized cognitive function, as measured by the Mini-Mental State Examination (MMSE), while the placebo group experienced typical decline.

This pausing of progression represents the first human trial evidence of microdosing cannabinoids potentially halting Alzheimer’s-related cognitive deterioration without significant side effects.

Described as unprecedented, the approach leverages the endocannabinoid system’s role in neuroprotection, which naturally diminishes with age. Though promising, the study’s small sample size and limited scope to certain cognitive metrics highlight the need for larger, longer trials to confirm efficacy and safety.

Current Alzheimer’s therapies offer minimal benefit and often severe side effects, making this low-risk cannabinoid option a hopeful avenue amid rising dementia cases globally.